Axoglatiran® FS: Generic of Copaxone® Preparation Based on Glatiramer Acetate
- Authors: Skornyakov Y.V.1, Deryabin A.A.2, Skornyakova O.V.3
- 
							Affiliations: 
							- Nordic Chemical Co., Ministry of Health of Russia
- Perm Chemical Co.
- M. V. Lomonosov Moscow State University
 
- Issue: Vol 51, No 4 (2017)
- Pages: 301-306
- Section: Drugs
- URL: https://ogarev-online.ru/0091-150X/article/view/244582
- DOI: https://doi.org/10.1007/s11094-017-1603-6
- ID: 244582
Cite item
Abstract
General information about the synthesis and properties of glatiramer acetate (GA) drug substance and the principles and methods for verifying the pharmaceutical identity of GA drug substance and Copaxone® and generic Axoglatiran® FS (INN) that are based on it was presented. Registration certificate No. LP-003572 dated Apr. 18, 2016, was issued by the RF for the first domestic GA-based generic drug Axoglatiran® FS.
Keywords
About the authors
Yu. V. Skornyakov
Nordic Chemical Co., Ministry of Health of Russia
							Author for correspondence.
							Email: skorn506@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 123001						
A. A. Deryabin
Perm Chemical Co.
														Email: skorn506@mail.ru
				                					                																			                												                	Russian Federation, 							Perm, 614034						
O. V. Skornyakova
M. V. Lomonosov Moscow State University
														Email: skorn506@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 119991						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					